xRead - Nonallergic Rhinitis (September 2025)

15314995, 2023, 12, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/lary.30706 by University Of Chicago, Wiley Online Library on [15/07/2025]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

>1 h daily at least 4 /7 days a week Symptom control assessment (Scale 0 – 4) At least 2 – 3 weeks/month during 6 months of last year Nasal examination, Nasal cytology 18 to 75

Negative allergy skin tests Quality of Life questionnaire (Scale 1 – 5) Safety 43.5 30.5 Severity (Scale 0 – 5) and duration of rhinorrhea

Negative allergy skin tests Quality of life evaluation (Scale 1 – 4) Safety

39.6 29.8 Severity (Scale 0 – 5) and duration of rhinorrhea/other nasal symptoms

Doube blind Ipratropium 46.1 71.4 Symptoms recorded on a standardized diary card at day 1 and 3 crossover study Day 2 no treatment None with URI/took intranasal sprays within the last 5days Rhinorrhea, sneezing, and nasal congestion 42 mcg in each nostril BID 28 Placebo (16) NAR 6 to 18 11.3 63 Severity (Scale 0 – 5) and duration of rhinorrhea Bromide (28) Day 1 80mcg 1 Placebo (28) Cold induced rhinitis with severe rhinorrhea

(%) Measured outcomes

Day 3 crossover None had nasal polyposis Graded based on visual analog scale from 0 to 10 cm Number of cleaning tissues used during day 1 and 3 Safety

>1 h daily at least 4 /7 days a week Effects on postnasal drip, sneezing, congestion At least 2 – 3 weeks/month during 6 months of last year Nasal rebound symptoms Minimum severity of mild nasal secretions Nasal examination, Nasal cytology 14 to 53

Watery discharge >1 h per day Secretory response to Metacholine challenge Negative allergy skin tests Normal Rhinoscopy 18 to 75

40 or 80 mcg in each nostril 1 Placebo (3) NAR, rhinitis duration >1 yr 24 to 53 42.9 66 Duration of effect

Duration of nasal congestion and sneezing Nasal examination, Nasal cytology Quality of life evaluation Safety

Male

age

Mean

Age

(year)

(n) Included patients

NAR, Rhinorrhoea in the preceding month

42 mcg in each nostril TID 56 Placebo (84) NAR, Rhinorrhoea in the preceding month

TABLE I.

56 Placebo (116)

Comparison

Overview of the Studies Included in this Review.

Duration (day)

Study Design Intervention (n) Dose

42 mcg in each nostril TID

Bronsky et al, 1995 Double blind RCT Ipratropium Bromide (117)

Becker et al, 1997 Double blind RCT Ipratropium Bromide (3)

metacholine challenge

Georgitis et al, 1994 Double blind RCT Ipratropium Bromide (90)

Meltzer et al, 1997 Double blind RCT Ipratropium Bromide (15)

Followed by

Abbreviations: BID, twice per day; mcg, micrograms; NAR, non-allergic rhinitis; RCT, Randomized controlled trials; TID, three times per day.

et al, 2001

Bonadonna

Laryngoscope 133: December 2023

El Khoury et al.: Ipratropium Bromide in Non-Allergic Rhinitis 3249